Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

2012351 citationsJournal Articlebronze Open Access

Authors

Steven Boonen · KU Leuven

Jean‐Yves Reginster · University of Liège

Jean‐Marc Kaufman · Ghent University Hospital

Kurt Lippuner · University of Bern

José Zanchetta · Universidad del Salvador

Bente Langdahl · Aarhus University Hospital

René Rizzoli ·

Abstract

Zoledronic acid treatment was associated with a significantly reduced risk of vertebral fracture among men with osteoporosis. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT00439647.).

Topics & Keywords

Bone health and osteoporosis research Bone health and treatments Bone and Joint Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 367, Issue 18, pp. 1714-1723

DOI: 10.1056/nejmoa1204061

Field-Weighted Citation Impact: 24.08